IL116083A - Liquid pharmaceutical compositions containing ondanseteron and sorbitol as sweetener - Google Patents

Liquid pharmaceutical compositions containing ondanseteron and sorbitol as sweetener

Info

Publication number
IL116083A
IL116083A IL11608395A IL11608395A IL116083A IL 116083 A IL116083 A IL 116083A IL 11608395 A IL11608395 A IL 11608395A IL 11608395 A IL11608395 A IL 11608395A IL 116083 A IL116083 A IL 116083A
Authority
IL
Israel
Prior art keywords
sweetener
pct
ondanseteron
sorbitol
pharmaceutical compositions
Prior art date
Application number
IL11608395A
Other languages
English (en)
Other versions
IL116083A0 (en
Original Assignee
Glaxo Welcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL116083(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Welcome Inc filed Critical Glaxo Welcome Inc
Publication of IL116083A0 publication Critical patent/IL116083A0/xx
Publication of IL116083A publication Critical patent/IL116083A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Dental Preparations (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11608395A 1994-11-22 1995-11-21 Liquid pharmaceutical compositions containing ondanseteron and sorbitol as sweetener IL116083A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9423588A GB9423588D0 (en) 1994-11-22 1994-11-22 Compositions

Publications (2)

Publication Number Publication Date
IL116083A0 IL116083A0 (en) 1996-01-31
IL116083A true IL116083A (en) 2000-09-28

Family

ID=10764811

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11608395A IL116083A (en) 1994-11-22 1995-11-21 Liquid pharmaceutical compositions containing ondanseteron and sorbitol as sweetener

Country Status (33)

Country Link
US (1) US5854270A (de)
EP (1) EP0792149B1 (de)
JP (1) JP2965704B2 (de)
KR (1) KR100292124B1 (de)
CN (1) CN1108153C (de)
AT (1) ATE196084T1 (de)
AU (1) AU703932B2 (de)
BE (1) BE1009458A5 (de)
BR (1) BR9509807A (de)
CA (1) CA2205546C (de)
CY (1) CY2171B1 (de)
CZ (1) CZ285187B6 (de)
DE (1) DE69518767T2 (de)
DK (1) DK0792149T3 (de)
ES (1) ES2151083T3 (de)
FI (1) FI119356B (de)
FR (1) FR2727015B1 (de)
GB (2) GB9423588D0 (de)
GR (1) GR3034684T3 (de)
HK (1) HK1009590A1 (de)
HU (1) HU226947B1 (de)
IE (1) IE950884A1 (de)
IL (1) IL116083A (de)
IT (1) IT1282353B1 (de)
NO (1) NO306892B1 (de)
NZ (1) NZ297879A (de)
PL (1) PL181522B1 (de)
PT (1) PT792149E (de)
RU (1) RU2145853C1 (de)
SI (1) SI0792149T1 (de)
TW (1) TW413634B (de)
WO (1) WO1996015786A2 (de)
ZA (1) ZA959820B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162561B1 (es) * 1999-06-28 2002-07-16 Boehringer Ingelheim Espana Composicion farmaceutica de metamizol oral, liquida, transparente, estable y de sabor aceptable.
US6473876B1 (en) 1999-06-29 2002-10-29 Sony Corporation Method and apparatus for encoding of bitstreams using rotation
CA2380524A1 (en) * 1999-08-25 2001-03-01 Barrett R. Cooper Compositions and methods for treating opiate intolerance
EP1339707A2 (de) * 2000-10-30 2003-09-03 Teva Pharmaceutical Industries Ltd. Neue kristall- und solvatformen von ondansetronhydrochlorid und verfahren zu deren herstellung
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
CA2480826C (fr) * 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US7098345B2 (en) * 2002-04-29 2006-08-29 TEVA Gyógyszergyár Zárkörüen Müködö Részvénytársaság Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
DE20320528U1 (de) * 2002-04-30 2004-09-16 Teva Pharmaceuticals Usa, Inc. Neue Kristallformen von Ondansetron und Arzneimittel, welche die neuen Formen enthalten
CA2505990C (en) * 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
CN100423779C (zh) * 2006-09-27 2008-10-08 中国药科大学 一种以5－羟色胺3受体拮抗剂和h2受体拮抗剂为活性成分的药用组合物及其制药用途
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
US8124126B2 (en) 2008-01-09 2012-02-28 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2011034568A1 (en) 2009-09-18 2011-03-24 Chase Pharmaceuticals Corporation Method and composition for treating alzheimer-type dementia
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
EP2451274B1 (de) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
US20120302616A1 (en) * 2010-12-03 2012-11-29 Nikhilesh Singh Method of treatment of obsessive compulsive disorder with ondansetron
KR101058749B1 (ko) * 2010-12-29 2011-08-24 에스씨바이오팜 주식회사 네오헤스피리딘 디하이드로찰콘을 감미료로 사용하는 온단세트론 염산염 이수화물 함유 액상 조성물
BR122016020433A2 (pt) 2012-09-05 2019-08-27 Chase Pharmaceuticals Corp combinação farmacêutica e uso de um nspacha e de um achei e, opcionalmente, de um naaea
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
KR101635820B1 (ko) * 2015-10-30 2016-07-04 재단법인 통합의료진흥원 온단세트론 및 반하후박탕을 포함하는 항암치료 보조용 조성물
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
KR101721094B1 (ko) * 2016-09-09 2017-03-29 재단법인 통합의료진흥원 댕댕이나무 열매 추출물을 포함하는 오심 및 구토 치료 효과 증진용 조성물
KR102675602B1 (ko) * 2023-09-01 2024-06-14 (주)옥천당 항암제 투여시 유발되는 소화관 장애의 효과적 제어가 가능한 신규 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL190373C (nl) * 1984-01-25 1994-02-01 Glaxo Group Ltd Een 3-gesubstitueerde aminomethyl-2,3-dihydro-4(1h)-carbazolon, werkwijze ter bereiding daarvan, alsmede een farmaceutisch preparaat.
JPH0648960A (ja) * 1990-02-22 1994-02-22 Glaxo Group Ltd 医 薬
ITMI922854A1 (it) * 1992-12-15 1994-06-15 Boehringer Ingelheim Italia Uso degli antagonisti dei recettori 5-ht3

Also Published As

Publication number Publication date
IT1282353B1 (it) 1998-03-20
BR9509807A (pt) 1997-10-21
NO972324L (no) 1997-07-21
CA2205546C (en) 2000-01-25
CY2171B1 (en) 2002-08-23
PL320288A1 (en) 1997-09-15
AU703932B2 (en) 1999-04-01
RU2145853C1 (ru) 2000-02-27
GB9423588D0 (en) 1995-01-11
DK0792149T3 (da) 2000-12-18
ATE196084T1 (de) 2000-09-15
HUT77944A (hu) 1998-12-28
DE69518767T2 (de) 2001-05-31
FI119356B (fi) 2008-10-31
ES2151083T3 (es) 2000-12-16
JPH10508866A (ja) 1998-09-02
FR2727015B1 (fr) 1997-08-22
IL116083A0 (en) 1996-01-31
NO972324D0 (no) 1997-05-21
CN1108153C (zh) 2003-05-14
ZA959820B (en) 1996-07-29
KR970706815A (ko) 1997-12-01
EP0792149A2 (de) 1997-09-03
TW413634B (en) 2000-12-01
AU4313596A (en) 1996-06-17
NZ297879A (en) 1998-12-23
GB9523666D0 (en) 1996-01-24
DE69518767D1 (de) 2000-10-12
ITRM950763A0 (de) 1995-11-20
CA2205546A1 (en) 1996-05-30
FI972168A (fi) 1997-05-21
FR2727015A1 (fr) 1996-05-24
KR100292124B1 (ko) 2001-07-12
GB2295317B (en) 1998-11-25
CN1171740A (zh) 1998-01-28
EP0792149B1 (de) 2000-09-06
HU226947B1 (en) 2010-03-29
SI0792149T1 (en) 2001-02-28
HK1009590A1 (en) 1999-06-04
IE950884A1 (en) 1996-05-29
US5854270A (en) 1998-12-29
JP2965704B2 (ja) 1999-10-18
CZ285187B6 (cs) 1999-06-16
FI972168A0 (fi) 1997-05-21
BE1009458A5 (fr) 1997-04-01
PL181522B1 (en) 2001-08-31
ITRM950763A1 (it) 1997-05-20
WO1996015786A2 (en) 1996-05-30
PT792149E (pt) 2001-02-28
CZ154897A3 (en) 1997-10-15
NO306892B1 (no) 2000-01-10
WO1996015786A3 (en) 1996-06-27
GB2295317A (en) 1996-05-29
GR3034684T3 (en) 2001-01-31
MX9703734A (es) 1997-09-30

Similar Documents

Publication Publication Date Title
IL116083A (en) Liquid pharmaceutical compositions containing ondanseteron and sorbitol as sweetener
GB2295318B (en) Freeze-dried dosage form containing ondansetron
AU3254395A (en) Use of a combination product that contains a competitive progesterone antagonist and a gestagen for the production of a pharmaceutical agent for treating endometriosis or leiomyomata uteri
ES2196079T3 (es) Procedimiento de fabricacion de unidades posologicas por medio de una granulacion por via humeda.
DK0758241T3 (da) Anvendelse af visse methanbisphosphonsyrederivater til at hindre løsning og vandring af proteser

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired